{"id":"NCT01006629","sponsor":"Abbott","briefTitle":"Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children","officialTitle":"A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-11","primaryCompletion":"2010-04","completion":"2010-07","firstPosted":"2009-11-03","resultsPosted":"2011-07-19","lastUpdate":"2011-07-19"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infection","Premature Birth","Bronchopulmonary Dysplasia","Congenital Heart Disease"],"interventions":[{"type":"BIOLOGICAL","name":"palivizumab","otherNames":["ABT-315 (MEDI-493)","Synagis 15 mg/kg intramuscularly"]}],"arms":[{"label":"palivizumab","type":"EXPERIMENTAL"}],"summary":"100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.","primaryOutcome":{"measure":"Frequency of Adverse Events","timeFrame":"Through 30 days following the last injection of palivizumab","effectByArm":[{"arm":"Palivizumab","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["Russia"]},"refs":{"pmids":["22943074"],"seeAlso":["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23151&CFID"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":100},"commonTop":["Rhinitis","Upper respiratory tract infection","Bronchitis","Bronchopulmonary dysplasia","Teething"]}}